Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions

Reuters

06-19

Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions

Insulet Corporation has announced its participation in the upcoming American Diabetes Association $(ADA.AU)$ 85th Scientific Sessions scheduled from June 20 to 23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. During the event, Insulet plans to share detailed insights from its groundbreaking SECURE-T2D and RADIANT trials, focusing on the impact of Omnipod® 5 on improved health outcomes for people with diabetes. The company will present real-world glycemic outcomes data from over 23,000 individuals with type 2 diabetes in the United States using Omnipod 5. Additionally, Insulet will engage attendees with booth activities, including podcasts, hands-on demonstrations, and immersive experiences. Results from these trials were previously presented at last year's ADA conference, with further insights set to be disclosed at this year's sessions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250619043429) on June 19, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2544168071"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544168071\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2544168071?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-19 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544168071","market":"nz","top_or_hot":-1,"title":"Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Insulet Corporation has announced its participation in the upcoming American Diabetes Association <a href=\"https://laohu8.com/S/ADA.AU\">$(ADA.AU)$</a> 85th Scientific Sessions scheduled from June 20 to 23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. During the event, Insulet plans to share detailed insights from its groundbreaking SECURE-T2D and RADIANT trials, focusing on the impact of Omnipod® 5 on improved health outcomes for people with diabetes. The company will present real-world glycemic outcomes data from over 23,000 individuals with type 2 diabetes in the United States using Omnipod 5. Additionally, Insulet will engage attendees with booth activities, including podcasts, hands-on demonstrations, and immersive experiences. Results from these trials were previously presented at last year's ADA conference, with further insights set to be disclosed at this year's sessions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250619043429) on June 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-19 18:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Insulet Corporation has announced its participation in the upcoming American Diabetes Association <a href=\"https://laohu8.com/S/ADA.AU\">$(ADA.AU)$</a> 85th Scientific Sessions scheduled from June 20 to 23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. During the event, Insulet plans to share detailed insights from its groundbreaking SECURE-T2D and RADIANT trials, focusing on the impact of Omnipod® 5 on improved health outcomes for people with diabetes. The company will present real-world glycemic outcomes data from over 23,000 individuals with type 2 diabetes in the United States using Omnipod 5. Additionally, Insulet will engage attendees with booth activities, including podcasts, hands-on demonstrations, and immersive experiences. Results from these trials were previously presented at last year's ADA conference, with further insights set to be disclosed at this year's sessions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250619043429) on June 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065170008.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250619:nNDL6ytM94:1","article_id":"2544168071","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544168071","pubTimestamp":1750327224,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Insulet Corporation has announced its participation in the upcoming American Diabetes Association  85th Scientific Sessions scheduled from June 20 to 23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. During the event, Insulet plans to share detailed insights from its groundbreaking SECURE-T2D and RADIANT trials, focusing on the impact of Omnipod 5 on improved health outcomes for people with diabetes. The company will present real-world glycemic outcomes data from over 23,000 individuals with type 2 diabetes in the United States using Omnipod 5. Additionally, Insulet will engage attendees with booth activities, including podcasts, hands-on demonstrations, and immersive experiences. Results from these trials were previously presented at last year's ADA conference, with further insights set to be disclosed at this year's sessions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4588":"碎股","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4082":"医疗保健设备","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","PODD":"银休特","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","BK4551":"寇图资本持仓","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","BK4566":"资本集团"},"translate_title":"Insulet Corporation在ADA科学会议上公布突破性试验结果和新的Omnipod 5见解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PODD":0.9},"content_text":"Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions\n    \n\n        Insulet Corporation has announced its participation in the upcoming American Diabetes Association $(ADA.AU)$ 85th Scientific Sessions scheduled from June 20 to 23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. During the event, Insulet plans to share detailed insights from its groundbreaking SECURE-T2D and RADIANT trials, focusing on the impact of Omnipod® 5 on improved health outcomes for people with diabetes. The company will present real-world glycemic outcomes data from over 23,000 individuals with type 2 diabetes in the United States using Omnipod 5. Additionally, Insulet will engage attendees with booth activities, including podcasts, hands-on demonstrations, and immersive experiences. Results from these trials were previously presented at last year's ADA conference, with further insights set to be disclosed at this year's sessions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250619043429) on June 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}